Centogene Future Growth

Future criteria checks 1/6

Centogene's earnings are forecast to decline at 5.7% per annum while its annual revenue is expected to grow at 12.4% per year. EPS is expected to grow by 27.4% per annum.

Key information

-5.7%

Earnings growth rate

27.4%

EPS growth rate

Healthcare earnings growth15.9%
Revenue growth rate12.4%
Future return on equityn/a
Analyst coverage

Low

Last updated19 Jan 2024

Recent future growth updates

Recent updates

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Dec 21
Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Centogene GAAP EPS of -€0.28, revenue of €10.32M

Jul 15

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Nov 25
Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Jun 29
Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Centogene reports Q1 results

Jun 16

Centogene, Alector initiate EFRONT study in frontotemporal dementia

Jun 02

Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting

May 26

Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)

Apr 17
Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)

What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own?

Mar 05
What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own?

Update: Centogene (NASDAQ:CNTG) Stock Gained 11% In The Last Year

Jan 29
Update: Centogene (NASDAQ:CNTG) Stock Gained 11% In The Last Year

Is Centogene (NASDAQ:CNTG) A Risky Investment?

Dec 18
Is Centogene (NASDAQ:CNTG) A Risky Investment?

Centogene reports Q3 results

Dec 16

Centogene and Alnylam launch a clinical screening program targeting rare hereditary disease

Dec 08

Centogene expands partnership with PTC Therapeutics in rare genetic disorder

Nov 25

Earnings and Revenue Growth Forecasts

NasdaqGM:CNTG - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202460-45N/AN/A1
12/31/202349-49N/AN/A1
6/30/202351-40-29-26N/A
3/31/202349-40-27-24N/A
12/31/202247-39-29-26N/A
9/30/2022-15-44-29-28N/A
6/30/20222-58-31-29N/A
3/31/2022190-44-34-32N/A
12/31/202142-57-27-22N/A
9/30/2021162-40313N/A
6/30/2021168-24115N/A
3/31/2021126-27-513N/A
1/1/202138-60-88N/A
9/30/202073-30-36-24N/A
6/30/202049-28-31-21N/A
3/31/202050-24-17-9N/A
12/31/201949-21-15-8N/A
9/30/201944-19-13-4N/A
6/30/201945-16-11-3N/A
3/31/201943-13-16-6N/A
12/31/201840-11-16-5N/A
9/30/201839-9-21-4N/A
12/31/201732-5-22-4N/A
12/31/201628-5N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNTG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNTG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNTG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CNTG's revenue (12.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: CNTG's revenue (12.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CNTG's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.